Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PepGNP-Dengue
- Development stage
- Phase 1
- Lead developer
- Gylden Pharma
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
PepGNP-Dengue is a synthetic, nanoparticle-based T-cell priming peptide vaccine developed by Gylden Pharma (formerly Emergex Vaccines) for the prevention of Dengue fever. The vaccine utilizes a gold nanoparticle (GNP) platform to deliver a cocktail of synthetic peptides representing conserved regions across all four Dengue virus (DENV) serotypes. Unlike traditional vaccines that primarily aim to induce neutralizing antibodies, PepGNP-Dengue is designed to prime naive CD8+ T-cells to generate virus-specific cytotoxic T lymphocytes (CTLs). These CTLs identify and eliminate infected cells before productive viral replication can occur, potentially providing broad protection while mitigating the risk of antibody-dependent enhancement (ADE). The candidate has completed Phase I clinical testing, demonstrating a favorable safety profile and the induction of specific T-cell memory subsets.
- Other names
- naNO-DENGUE
02
Targets
γδ TCR (T-cell receptor)MHC I (MHC class I})
Beyond the preview
Go deeper on PepGNP-Dengue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PepGNP-Dengue.